Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Voxel-Wise Case-Control Analysis of Dose, Linear Energy Transfer, and Symptomatic Brainstem Necrosis in Pediatric Brain Tumors Treated With Proton Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

DENTALE: a validated Dentofacial EvaluatioN Tool to standardize radiological Assessment of Late dental and maxillofacial adverse Effects following treatment for pediatric rhabdomyosarcoma.

Frontiers in pediatrics·2026
Same author

Noisy probing dose facilitated dose prediction for pencil beam scanning proton therapy: Physics enhances generalizability.

Medical physics·2026
Same author

Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Robust Four-Field and Arc LET-Optimized Proton Prostate Cancer Treatment Plans With Urethral Sparing.

International journal of particle therapy·2026
Same author

Particle Therapy Co-Operative Group Consensus Statement on Reirradiation With Proton Therapy for Prostate Cancer.

International journal of particle therapy·2026

Related Experiment Video

Updated: Jun 21, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Erectile dysfunction after radiotherapy for prostate cancer.

William M Mendenhall1, Randal H Henderson, Daniel J Indelicato

  • 1Department of Radiation Oncology, University of Florida Health Science Center, 2000 SW Archer Rd, PO Box 100385 Gainesville, FL 32610-0385, USA. mendwm@shands.ufl.edu

American Journal of Clinical Oncology
|August 7, 2009
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) is common after prostate cancer radiotherapy. Early use of phosphodiesterase inhibitors may reduce the risk of ED following treatment.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 21, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Oncology
  • Urology
  • Radiotherapy

Background:

  • Erectile dysfunction (ED) is a frequent complication following prostate cancer radiotherapy.
  • The exact causes of ED post-radiotherapy are not fully understood.
  • Potential contributing factors include patient age, baseline erectile function, and androgen deprivation therapy.

Purpose of the Study:

  • To investigate the etiology of erectile dysfunction after prostate cancer radiotherapy.
  • To explore the relationship between radiation dose to penile structures and ED development.
  • To assess the potential benefit of early phosphodiesterase inhibitor use in mitigating ED.

Main Methods:

  • Review of existing literature on prostate cancer radiotherapy and erectile dysfunction.
  • Analysis of factors associated with ED, including patient characteristics and treatment parameters.
  • Evaluation of the role of specific radiation doses to penile structures (penile bulb, corpora cavernosa).

Main Results:

  • Erectile dysfunction is a common outcome after prostate cancer radiotherapy.
  • Factors like age, pretreatment function, and androgen deprivation therapy are implicated.
  • The specific radiation dose to penile structures and its link to ED requires further investigation.
  • Early administration of phosphodiesterase inhibitors may decrease the incidence of ED.

Conclusions:

  • Erectile dysfunction following prostate cancer radiotherapy is multifactorial.
  • Further research is needed to clarify the dose-response relationship for penile structures.
  • Early intervention with phosphodiesterase inhibitors is a promising strategy to manage or prevent ED.